These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 8687151)
1. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Friess H; Beger HG; Kunz J; Funk N; Schilling M; Büchler MW Anticancer Res; 1996; 16(2):915-20. PubMed ID: 8687151 [TBL] [Abstract][Full Text] [Related]
2. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study. Huber R; Lüdtke R; Klassen M; Müller-Buscher G; Wolff-Vorbeck G; Scheer R Eur J Med Res; 2001 Sep; 6(9):399-405. PubMed ID: 11669085 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. Goebell PJ; Otto T; Suhr J; Rübben H J Urol; 2002 Jul; 168(1):72-5. PubMed ID: 12050495 [TBL] [Abstract][Full Text] [Related]
4. Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study. Schumacher K; Schneider B; Reich G; Stiefel T; Stoll G; Bock PR; Hanisch J; Beuth J Anticancer Res; 2003; 23(6D):5081-7. PubMed ID: 14981970 [TBL] [Abstract][Full Text] [Related]
5. [Ingredients of mistletoe (Viscum album L.) as potential drugs]. Franz H Pharmazie; 1985 Feb; 40(2):97-104. PubMed ID: 3889937 [No Abstract] [Full Text] [Related]
6. [Problems of randomized studies in complementary medicine demonstrated in a study on mistletoe treatment of patients with breast cancer]. Gerhard I; Abel U; Loewe-Mesch A; Huppmann S; Kuehn JJ Forsch Komplementarmed Klass Naturheilkd; 2004 Jun; 11(3):150-7. PubMed ID: 15249749 [TBL] [Abstract][Full Text] [Related]
7. [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice]. Farzad M; De Luca MC; Rubino G; Pirtoli L; Pepi F; Sebaste L; Ponticelli P; Atzeni G; Maranzano E; Silvano G Radiol Med; 2001; 102(1-2):72-7. PubMed ID: 11677442 [TBL] [Abstract][Full Text] [Related]
8. Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs. Weber K; Mengs U; Schwarz T; Hajto T; Hostanska K; Allen TR; Weyhenmeyer R; Lentzen H Arzneimittelforschung; 1998 May; 48(5):497-502. PubMed ID: 9638318 [TBL] [Abstract][Full Text] [Related]
9. Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study. Friedel WE; Matthes H; Bock PR; Zänker KS J Soc Integr Oncol; 2009; 7(4):137-45. PubMed ID: 19883529 [TBL] [Abstract][Full Text] [Related]
10. A phase II trial of marimastat in advanced pancreatic cancer. Evans JD; Stark A; Johnson CD; Daniel F; Carmichael J; Buckels J; Imrie CW; Brown P; Neoptolemos JP Br J Cancer; 2001 Dec; 85(12):1865-70. PubMed ID: 11747327 [TBL] [Abstract][Full Text] [Related]
11. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals. Klein R; Classen K; Berg PA; Lüdtke R; Werner M; Huber R Eur J Med Res; 2002 Apr; 7(4):155-63. PubMed ID: 12010650 [TBL] [Abstract][Full Text] [Related]
12. Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Lenartz D; Dott U; Menzel J; Schierholz JM; Beuth J Anticancer Res; 2000; 20(3B):2073-6. PubMed ID: 10928154 [TBL] [Abstract][Full Text] [Related]
13. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Semiglazov VF; Stepula VV; Dudov A; Schnitker J; Mengs U Anticancer Res; 2006; 26(2B):1519-29. PubMed ID: 16619567 [TBL] [Abstract][Full Text] [Related]
14. From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe? Gabius HJ; Gabius S; Joshi SS; Koch B; Schroeder M; Manzke WM; Westerhausen M Planta Med; 1994 Feb; 60(1):2-7. PubMed ID: 8134410 [TBL] [Abstract][Full Text] [Related]
15. [Value of mistletoe lectin standardized mistletoe extract for evaluating antitumor properties]. Mengs U; Witthohn K; Schwarz T; Lentzen H Wien Med Wochenschr; 1999; 149(8-10):262-4. PubMed ID: 10483695 [TBL] [Abstract][Full Text] [Related]
16. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Piao BK; Wang YX; Xie GR; Mansmann U; Matthes H; Beuth J; Lin HS Anticancer Res; 2004; 24(1):303-9. PubMed ID: 15015612 [TBL] [Abstract][Full Text] [Related]
17. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Semiglasov VF; Stepula VV; Dudov A; Lehmacher W; Mengs U Anticancer Res; 2004; 24(2C):1293-302. PubMed ID: 15154663 [TBL] [Abstract][Full Text] [Related]
18. [Influence of ML-1 standardized mistletoe extract on the quality of life in head and neck cancer patients]. Steuer-Vogt MK; Bonkowsky V; Scholz M; Fauser C; Licht K; Ambrosch P HNO; 2006 Apr; 54(4):277-86. PubMed ID: 16132877 [TBL] [Abstract][Full Text] [Related]
19. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). Grossarth-Maticek R; Ziegler R Eur J Med Res; 2008 Mar; 13(3):107-20. PubMed ID: 18499556 [TBL] [Abstract][Full Text] [Related]
20. [Blood and tissue eosinophilia, mistletoe lectin antibodies and quality of life in a breast cancer patient undergoing intratumoral and subcutaneous mistletoe therapy]. Kröz M; Schad F; Matthes B; Pickartz H; Girke M Forsch Komplementarmed Klass Naturheilkd; 2002 Jun; 9(3):160-7. PubMed ID: 12119512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]